SCN2A-Related Developmental and Epileptic Encephalopathy

1. Disease Information

Overview. SCN2A-related developmental and epileptic encephalopathy (SCN2A-DEE) is a rare, autosomal-dominant, monogenic neurodevelopmental disorder caused by pathogenic variants in SCN2A, the gene encoding the α-subunit of the brain voltage-gated sodium channel Na_V1.2. It sits within a broad SCN2A-related phenotypic spectrum that ranges from benign self-limited neonatal/infantile epilepsy through severe early- and late-onset epileptic encephalopathy to autism spectrum disorder and intellectual disability without epilepsy. The "DEE" label specifically denotes the phenotype where refractory seizures co-occur with — and contribute to — developmental impairment.

The canonical OMIM disease entity is Developmental and Epileptic Encephalopathy 11 (DEE11), "an autosomal dominant seizure disorder characterized by neonatal or infantile onset of refractory seizures with resultant delayed neurologic development and persistent neurologic abnormalities" (OMIM #613721).

Key identifiers. - Gene: SCN2A — OMIM 182390; HGNC 10588 (hgnc:10588); chromosome 2q24.3; NCBI Gene 6326; UniProt Q99250 (SCN2A_HUMAN, Na_V1.2). - Disease: OMIM #613721 (DEE11). MONDO candidate: MONDO:0012588 (developmental and epileptic encephalopathy, 11) — verify against the broader "SCN2A-related" grouping term with OAK before binding. Orphanet: the SCN2A-DEE phenotype is captured under ORPHA entries for early infantile DEE / malignant migrating partial seizures of infancy (confirm exact ORPHA code). - ICD-10: G40.4 (other generalized epilepsy and epileptic syndromes) is the usual proxy code; ICD-11: 8A61 (developmental and epileptic encephalopathies). - MeSH: covered under "Spasms, Infantile" / "Epilepsy, Generalized" / "Epileptic Syndromes"; no SCN2A-specific MeSH descriptor.

Synonyms / alternative names: SCN2A encephalopathy; SCN2A-related epilepsy; DEE11; early infantile epileptic encephalopathy 11 (EIEE11, older term); SCN2A epileptic encephalopathy; Na_V1.2 channelopathy; benign familial neonatal-infantile seizures (BFNIS, the mild end of the same spectrum, distinct phenotype).

Data provenance: Information is drawn from aggregated disease-level resources (OMIM, Orphanet, GeneReviews, HPO) and cohort literature (Wolff et al. 2017; Sanders et al. 2018), not from individual EHR records. The large phenotype cohorts (e.g., Wolff 2017, n=201) are curated case aggregations rather than population EHR extractions.

Sources: OMIM #613721, OMIM 182390, MalaCards DEE11.

2. Etiology

Primary cause — genetic. SCN2A-DEE is caused by heterozygous pathogenic variants in SCN2A, the great majority arising de novo (new mutations not inherited from either parent). There is no infectious, environmental, or acquired cause of the core disorder; it is a pure monogenic channelopathy. The severity and clinical direction are set by how the variant alters Na_V1.2 biophysics:

• Gain-of-function (GoF) variants → increased channel activity/neuronal hyperexcitability → early-onset (<3 months) seizures / DEE.
• Loss-of-function (LoF) variants → reduced channel activity → late-onset (>3 months) epilepsy and/or autism/intellectual disability, often without early seizures.

"SCN2A pathogenic variants cause either gain or loss of channel function, which correlates well with the clinical phenotype. Gain-of-function variants are associated with early-onset seizures... whereas loss-of-function results in late-onset severe epilepsy and/or autism." (synthesized from the genotype–phenotype literature; Wolff et al. 2017, PMID 28379373; Sanders et al. 2018, PMID 30301539).

Genetic risk factors. The causal variant itself is the risk factor — there is no known common susceptibility locus. Recurrent DEE-causing GoF hotspots include p.Arg1882Gln (R1882Q) and p.Arg853Gln (R853Q) (note R853Q is functionally a LoF/mixed variant associated with later onset and treatment resistance), p.Leu1563Val, p.Glu1211Lys, and p.Met1770Leu, among others. De novo occurrence in a gene under strong evolutionary constraint (very low tolerance to LoF in gnomAD; high pLI) is the dominant "risk mechanism."

Environmental risk factors. None established for causation. Advanced paternal age is a general risk factor for de novo mutations across the genome and is a plausible (not disorder-specific) contributor. Sex is not a strong risk modifier (see §9). No toxin, infection, or occupational exposure is implicated.

Protective factors. None genetic or environmental are established for disease occurrence. On the therapeutic-response axis, the GoF-vs-LoF distinction is the closest thing to a "modifier": GoF patients respond to sodium-channel blockers, whereas the same drugs are ineffective or harmful in LoF patients — a functional-genotype modifier of outcome rather than of onset.

Gene–environment interactions. Not a meaningful axis for this monogenic disorder; the phenotype is variant-determined. Fever and intercurrent illness can trigger seizures (as in most epilepsies) but do not modify the underlying etiology.

Sources: Wolff et al. 2017, Brain, PubMed 28379373.

3. Phenotypes

The phenotype is bimodal along the GoF/LoF axis. Below, phenotypes are grouped with suggested HPO terms, onset, severity, course, and approximate frequency. Frequencies are cohort estimates (chiefly Wolff 2017, n=201; Sanders 2018) and should carry their own evidence when a frequency: band is asserted.

Core seizure / epilepsy phenotypes:

Developmental / neurological phenotypes:

Phenotype characteristics summary. - Onset: Bimodal — GoF ~neonatal to <3 months; LoF ~later infancy/childhood, sometimes with seizures only after 1–3 years or none at all (autism/ID-predominant). - Severity: Highly variable; recurrent GoF hotspots (e.g., R1882Q) trend toward the most severe DEE with profound ID. - Progression: Encephalopathy is typically static-to-progressive in early life; seizures may improve in childhood in ~50% even as developmental impairment persists — an important dissociation between seizure control and developmental trajectory. - QoL impact: Severe DEE causes profound dependence — non-verbal status, inability to walk, gastrostomy feeding, and high caregiver burden; the autism/ID-predominant LoF end causes lifelong support needs but with more preserved motor function.

Sources: OMIM #613721, Wolff et al. 2017, FamilieSCN2A clinical info.

4. Genetic / Molecular Information

Causal gene. SCN2A (Sodium Voltage-Gated Channel Alpha Subunit 2); HGNC:10588; OMIM 182390; 2q24.3. Encodes Na_V1.2, a ~2,005-aa transmembrane protein with four homologous domains (DI–DIV), each containing six segments (S1–S6); the S4 segments are voltage sensors and the DIII–DIV linker mediates fast inactivation. Na_V1.2 is expressed in the axon initial segment and unmyelinated/proximal axons of excitatory (glutamatergic) neurons, and dominates action-potential initiation and backpropagation early in development.

Pathogenic variants. - Type/class: Overwhelmingly de novo missense variants; also nonsense, frameshift, splice-site, and whole-gene deletions (the latter cluster on the LoF/autism-ID end). "SCN2A mutations are predominantly de novo missense mutations." - Classification: Per ACMG/AMP — many recurrent variants (R1882Q, R853Q, L1563V, etc.) are Pathogenic; novel missense variants are frequently VUS until functional testing resolves GoF vs LoF. Curate against ClinVar and ClinGen validity assertions (CGGV: if available). - Allele frequency: Essentially absent from population databases (gnomAD) — consistent with de novo, highly penetrant, deleterious variants. SCN2A is strongly LoF-constrained (high pLI/low LOEUF). - Somatic vs germline: Germline (de novo in the proband); rare parental germline/somatic mosaicism explains occasional recurrence in siblings (relevant to recurrence-risk counseling). - Functional consequence — the crux: - GoF: enhanced persistent current, impaired inactivation, hyperpolarizing shift of activation → neuronal hyperexcitability → early seizures. Sensitive to sodium-channel blockers. - LoF / haploinsufficiency: reduced current density, loss of function → later epilepsy and/or ASD/ID. Sodium-channel blockers ineffective or worsening. - Mixed variants: some variants show combined GoF+LoF biophysics (e.g., certain EIMFS variants), blurring the dichotomy (PMC9109789; Neurology Genetics 2025, PMC12854296).

Modifier genes. No robust modifier gene established. Genetic background likely modulates severity (as in mouse strains) but this is not clinically actionable.

Epigenetics / chromosomal abnormalities. No disorder-specific methylation signature is established. Large 2q24.3 deletions/CNVs spanning SCN2A (± neighboring SCN1A, SCN3A) produce contiguous-gene phenotypes and fall on the LoF/ASD-ID end — detectable by chromosomal microarray.

Suggested GO/gene annotations: SCN2A (hgnc:10588); GO:0005248 voltage-gated sodium channel activity; GO:0001518 voltage-gated sodium channel complex; GO:0019228 neuronal action potential; GO:0086010 membrane depolarization during action potential.

Sources: GeneCards SCN2A, Sanders et al. 2018 review PDF.

5. Environmental Information

Not a substantial contributor. SCN2A-DEE is monogenic and de novo. No toxin, radiation, pollution, occupational exposure, lifestyle factor, or infectious agent causes the disorder. As with epilepsy generally, fever, sleep deprivation, and intercurrent illness can provoke seizures in an already-established channelopathy, but these are triggers, not etiologic factors. This section is largely not applicable.

6. Mechanism / Pathophysiology

The central causal chain (GoF arm):

1. De novo GoF missense variant in SCN2A → altered Na_V1.2 gating (impaired fast inactivation, increased persistent Na⁺ current, hyperpolarized activation).
2. → Increased Na⁺ influx and neuronal hyperexcitability in glutamatergic cortical/hippocampal neurons (Na_V1.2 concentrated at the axon initial segment).
3. → Excitation–inhibition imbalance and hypersynchronous network firing.
4. → Recurrent seizures / status epilepticus beginning in the neonatal-to-early-infantile window.
5. → Epileptic encephalopathy: ongoing epileptiform activity plus the primary channel defect impair synaptic development → developmental delay, ID, and (in severe cases) regression.

This maps cleanly onto the dismech epilepsy_excitation_inhibition_imbalance module (conserved epilepsy pathway: ion-channel/synaptic dysfunction → excitation/inhibition imbalance → neuronal hyperexcitability and hypersynchrony → seizure generation → recurrent unprovoked seizures). The GoF arm is a textbook conformer at epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance.

The LoF arm (mechanistically distinct):

1. LoF/haploinsufficiency variant → reduced Na_V1.2 current.
2. → In immature neurons (where Na_V1.2 dominates AP initiation) → hypoexcitability and impaired action-potential firing/backpropagation → disrupted dendritic excitability, synaptic plasticity, and circuit maturation → ASD/ID.
3. → Paradoxically, in mature cortex, homeostatic/compensatory changes can produce network hyperexcitability and later-onset seizures — "immature glutamatergic cortical neurons from Scn2a+/− mice display decreased neuronal excitability, but mature neurons... are hyperexcitable."

This developmental-switch pathophysiology — the same gene causing hypoexcitability early and hyperexcitability late — is the mechanistic key to why one gene yields both autism-without-epilepsy and epilepsy phenotypes, and was worked out largely in mouse models (Spratt et al. 2019 Neuron; the Scn2a rodent-model review, PMC11601800).

Cell types / compartments involved: - Cell types (CL): glutamatergic/excitatory cortical pyramidal neuron (CL:0000598 pyramidal neuron; CL:0000679 glutamatergic neuron); hippocampal pyramidal neurons. Na_V1.2 is chiefly excitatory-neuron-restricted (contrast Na_V1.1/SCN1A in interneurons — hence the opposite drug logic). - Subcellular (GO CC): axon initial segment (GO:0043194); node of Ranvier / axolemma; plasma membrane voltage-gated sodium channel complex (GO:0001518). - Biological processes (GO): GO:0019228 neuronal action potential; GO:0086010 membrane depolarization during action potential; GO:0099509 regulation of presynaptic cytosolic calcium; GO:0050804 modulation of chemical synaptic transmission.

Protein dysfunction: Not misfolding/aggregation — this is a gating/biophysical defect. GoF variants shift the channel toward the open/non-inactivating state; LoF variants reduce functional channel density or trafficking. Functional consequence is resolved by patch-clamp electrophysiology and, increasingly, patient iPSC-derived neurons, which show "distinctive in vitro phenotypes" separating GoF and LoF cases (J Neurosci 2024, jneurosci.org/content/44/8/e0692232023).

Metabolic / immune involvement: None primary. No metabolic derangement, no autoimmune/inflammatory component. This is a pure electrical-signaling disorder — do not over-curate metabolic or immune mechanisms.

Tissue damage: No structural neurodegeneration is intrinsic; most brains are structurally normal on MRI (though rare cases with polymicrogyria/opercular dysplasia are reported — ScienceDirect S2950221724000242). "Damage" is functional — disrupted circuit development plus potential secondary injury from prolonged seizures/status epilepticus.

Molecular profiling / advanced tech: iPSC-derived neuron models (in vitro electrophysiology, GoF vs LoF separation); dynamic action-potential clamp; CRISPR-activation and cis-regulation functional-genomics rescue in mouse (SFARI 2025 report). Transcriptomic/proteomic disease signatures are model-derived, not clinical biomarkers.

Sources: J Neurosci iPSC study, Scn2a rodent model review PMC11601800, Sanders 2018.

7. Anatomical Structures Affected

• Organ / system: Central nervous system, primarily cerebral cortex and hippocampus (UBERON:0000955 brain; UBERON:0000956 cerebral cortex; UBERON:0002421 hippocampal formation). Body system: nervous system (UBERON:0001016). No primary involvement of other organ systems.
• Tissue/cell level: Gray-matter neuronal tissue; specifically excitatory glutamatergic pyramidal neurons (CL:0000598) of neocortex and hippocampus. GABAergic interneurons are relatively spared (mechanistically important — the inverse of SCN1A/Dravet).
• Subcellular: Axon initial segment (GO:0043194) and proximal axon — where Na_V1.2 sets AP threshold; also nodes of Ranvier and somatodendritic membrane for backpropagation.
• Localization / lateralization: Bilateral, diffuse cortical involvement; seizures may be focal/multifocal or generalized. Structural MRI is usually normal (bilateral, non-lesional). Rare malformation-of-cortical-development cases are the exception.

Sources: Sanders 2018, ScienceDirect polymicrogyria case.

8. Temporal Development

• Onset: Bimodal and variant-determined. GoF/DEE → neonatal to <3 months (often first days of life). LoF → >3 months to years, and the autism/ID-predominant subset may never develop epilepsy. Onset pattern is typically acute for seizures against a chronic/insidious developmental backdrop.
• Stages / course:
• Early-onset GoF DEE: neonatal seizures → possible evolution to West syndrome / infantile spasms (3–12 mo) → childhood epilepsy with variable control. Encephalopathy tracks alongside.
• Later-onset: childhood epilepsy, sometimes with movement disorder and episodic ataxia in the LoF spectrum.
• Progression rate: Variable. About half of patients achieve seizure freedom during childhood; the other half remain intractable (OMIM). Crucially, seizure improvement does not guarantee developmental improvement — cognitive impairment often persists.
• Course pattern: Chronic, lifelong. Seizures can be relapsing or evolve through age-dependent syndromes; developmental impairment is generally static-to-slowly-progressive rather than neurodegenerative.
• Critical periods: The early-infantile window is both the period of maximal seizure burden and the developmental window where intervention could most plausibly alter trajectory — the rationale for early functional testing to guide drug choice, and for the emerging ASO trials targeting infants.

Sources: OMIM #613721, Wolff et al. 2017.

9. Inheritance and Population

Epidemiology. - SCN2A-related disorders have an estimated prevalence around 8 per 100,000, with disease-causing variants arising in roughly 7.5 per 100,000 births (FamilieSCN2A / cohort estimates). Over 1,000 individuals have been identified worldwide, and numbers are rising with expanded genetic testing. For a structured Prevalence record: measure_type: BIRTH_PREVALENCE or POINT_PREVALENCE, prevalence_class: BAND_1_5_PER_10000, rate_per_100000: 7.5–8.0, with the source phrasing in notes. SCN2A is among the most frequently implicated single genes in DEE and in de novo ASD. - Incidence is not precisely established; de novo occurrence and ascertainment through sequencing complicate rate estimates.

Inheritance (genetic). - Pattern: Autosomal dominant (HP:0000006); the overwhelming majority are de novo (relationship_type causal; onset from a new heterozygous variant). - Penetrance: Effectively complete/high for pathogenic de novo DEE variants; the mild familial BFNIS end shows near-complete penetrance too but for a benign phenotype. - Expressivity: Highly variable — even the same recurrent variant can produce a range of severity. - Anticipation: Not applicable (not a repeat-expansion disorder). - Germline mosaicism: Documented (parental gonadal/somatic mosaicism) — recurrence risk to siblings is low but not zero (~1–2% empiric), which matters for counseling. - Founder effects / consanguinity: Not relevant — de novo dominant, no ancestry-specific founder alleles, no consanguinity role. - Carrier frequency: Not applicable (dominant, de novo).

Population demographics. - Affected populations: No ethnic/geographic predilection — occurs worldwide across all ancestries (expected for de novo dominant). - Sex ratio: Roughly equal (≈1:1); SCN2A is autosomal, so no strong sex bias, though ASD ascertainment can skew reported series slightly male. - Age distribution: Onset in neonatal period through early childhood; the population is predominantly pediatric, with a growing cohort of surviving adolescents/adults.

Sources: FamilieSCN2A clinical info, Decoding SCN2A Variants (J Clin Med 2025, PMC12156426).

10. Diagnostics

Genetic testing — the diagnostic anchor. - First-line: Next-generation sequencing — epilepsy/DEE gene panels, whole-exome sequencing (WES), or whole-genome sequencing (WGS) identify the causal SCN2A variant. Given the DEE presentation, early genetic testing is now standard of care because the result directly changes treatment (GoF → sodium-channel blockers; LoF → avoid them). MAXO: MAXO:0000922-family genetic testing / molecular diagnostic actions. - Chromosomal microarray (CMA): detects 2q24.3 deletions/CNVs involving SCN2A (LoF/ASD-ID end). - Single-gene SCN2A testing: appropriate when the phenotype strongly suggests it (e.g., neonatal-onset SCB-responsive seizures). - Variant interpretation: ACMG/AMP classification via ClinVar/ClinGen; functional characterization (patch-clamp, iPSC-neuron electrophysiology) is increasingly used to resolve GoF vs LoF for VUS and to guide therapy — arguably the most consequential "diagnostic" beyond variant detection.

Clinical / supportive tests: - EEG: seizure characterization; may show multifocal epileptiform discharges, hypsarrhythmia (if West syndrome), or migrating focal ictal patterns. Emerging work explores EEG features as correlates of variant function and outcome (medRxiv 2023.10.24.23296360). - Brain MRI: usually normal; excludes structural/malformative mimics (rare polymicrogyria/opercular dysplasia cases exist). - Metabolic workup / lumbar puncture: typically normal — used mainly to exclude treatable metabolic epilepsies (e.g., pyridoxine-dependent, GLUT1) in the differential before or alongside genetic testing.

Differential diagnosis: other DEE genes — SCN1A (Dravet; note opposite drug logic), SCN8A, KCNQ2, KCNT1 (EIMFS), STXBP1, CDKL5, PRRT2; treatable metabolic epilepsies (pyridoxine-dependent/ALDH7A1, PNPO deficiency, GLUT1). The distinguishing feature is the SCN2A variant plus its functional direction and the SCB-response pattern.

Screening: No population newborn screening. Cascade testing of parents (for recurrence risk and mosaicism) and reproductive counseling (prenatal/PGT for a known familial variant, chiefly relevant to mosaic parents) apply.

Sources: Efficacy of sodium channel blockers, PMID 27876397, EEG insights medRxiv.

11. Outcome / Prognosis

• Survival / mortality: No single reliable survival figure; life expectancy is reduced in severe DEE, with risk of SUDEP (sudden unexpected death in epilepsy), status epilepticus, and complications of profound disability (aspiration, respiratory infection). Milder LoF/ASD-ID phenotypes have near-normal life expectancy.
• Morbidity / disability: Severe DEE → profound intellectual disability, non-verbal status, motor impairment, need for gastrostomy and full-time care. This is the dominant burden.
• Disease course: ~50% achieve seizure freedom in childhood; the remainder have intractable epilepsy. Developmental/cognitive impairment frequently persists despite seizure control.
• Prognostic factors:
• Age of onset — earlier onset (neonatal GoF, especially recurrent severe variants like R1882Q) predicts worse developmental outcome.
• Functional variant class — GoF-early tends to be SCB-responsive (better seizure control) but can still carry severe encephalopathy; LoF/late is SCB-resistant.
• Specific variant identity — recurrent hotspots have characteristic severity signatures.
• Prognostic biomarkers: No validated molecular biomarker; variant function (GoF/LoF from electrophysiology or in-silico prediction) is the best available prognostic/therapeutic stratifier; EEG features under investigation.

Sources: Wolff et al. 2017, OMIM #613721.

12. Treatment

Treatment is genotype/function-directed — the single most important precision-medicine lesson in the whole disorder. It's the closest thing in epilepsy to reading the thermostat before you touch the dial.

Pharmacotherapy — the GoF/LoF split:

• GoF (early-onset, <3 months): Sodium-channel blockers (SCBs) are first-line and often effective. Agents: phenytoin, carbamazepine, oxcarbazepine, lacosamide, lamotrigine, zonisamide. Documented dramatic responses to IV phenytoin loading in refractory neonatal cases.

  "Patients with the early seizure onset respond better to antiepileptic drugs that non-selectively block sodium channel function, such as phenytoin." (Wong et al. 2016, PMID 27876397 — verify exact quote on fetch)

MAXO/agents: treatment_term NCIT:C15986 Pharmacotherapy; therapeutic_agent CHEBI — phenytoin (CHEBI:8107), carbamazepine (CHEBI:3387), lamotrigine (CHEBI:6367), oxcarbazepine (CHEBI:7822), lacosamide (CHEBI:31771 — verify), zonisamide (CHEBI:10127 — verify). therapeutic_modality: SMALL_MOLECULE.

• LoF (late-onset >3 months, and ASD/ID): SCBs are ineffective or can worsen seizures — avoid as monotherapy. Use broad-spectrum agents: levetiracetam, valproate, benzodiazepines, topiramate; and consider ketogenic diet (MAXO:0000088 dietary intervention / NCIT ketogenic diet term). Response is generally poorer than in the GoF group.

Precision / disease-modifying therapies (the frontier):

• Antisense oligonucleotides (ASOs) — GoF-directed. Elsunersen (PRAX-222), an intrathecally-administered ASO designed to selectively lower SCN2A expression in GoF patients, is the flagship program (Praxis Precision Medicines). In the EMBRAVE Phase 1/2 study, early data showed a 44% median seizure reduction after three monthly intrathecal doses; topline results were slated for the first half of 2026. Regulatory status: FDA Breakthrough Therapy Designation (June 2026), Orphan Drug, Rare Pediatric Disease designations, plus EMA Orphan/PRIME. Registrational trial NCT07019922 (recruiting); earlier NCT05737784. therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE; aso_mechanism: RNASE_H_KNOCKDOWN; target_gene: SCN2A (hgnc:10588). This maps to the dismech antisense_oligonucleotide_therapy#Pathogenic mRNA Accumulation conformance target (RNase-H knockdown paradigm). A published case reports ASO treatment in a preterm infant with early-onset SCN2A-DEE (PMC12283366 / PMC12854296-adjacent — verify).

• Upregulation strategies — LoF-directed (preclinical). Because LoF needs more Na_V1.2, ASO knockdown is exactly wrong; instead, CRISPR-activation (CRISPRa) and cis-regulation gene therapy to increase endogenous Scn2a expression have rescued neural excitability and behavioral phenotypes in Scn2a⁺/⁻ mice (SFARI 2025; ScienceDirect S266732582300033X). Still preclinical.

Supportive / rehabilitative: developmental therapies — physical therapy (MAXO:0000011), occupational therapy, speech therapy, feeding/nutrition support (gastrostomy where needed, MAXO supportive care MAXO:0000950), and management of comorbid autism/behavior. Genetic counseling (MAXO:0000079) for the family.

Pharmacogenomics: The operative "pharmacogenomic" axis here is the SCN2A variant's own functional class dictating SCB response — not classic CYP-based metabolism (though standard phenytoin/carbamazepine PGx — e.g., HLA-B*15:02 for carbamazepine SJS risk — still applies to those drugs).

Treatment strategy: Confirm variant → determine GoF vs LoF (functional data or informed prediction) → GoF: SCB first-line; LoF: avoid SCBs, use broad-spectrum ± ketogenic diet → escalate to precision ASO (GoF) as trials mature.

Sources: Praxis FDA Breakthrough release, NCT07019922, NCT05737784, Wong et al. PMID 27876397, SFARI cis-regulation rescue.

13. Prevention

• Primary prevention: None possible for a de novo dominant disorder — you can't prevent a new mutation. No vaccine, no modifiable risk factor.
• Secondary prevention / early detection: Rapid genetic diagnosis in a neonate/infant with unexplained seizures is the actionable lever — it enables function-directed treatment early, potentially reducing seizure burden and (hoped, unproven) improving developmental trajectory. This is prevention of complications, not of disease occurrence.
• Tertiary prevention: Optimizing seizure control (correct drug class), SUDEP-risk mitigation, managing feeding/respiratory complications, and developmental support to maximize function.
• Genetic counseling & reproductive options: For families with an affected child, counseling covers the low-but-nonzero sibling recurrence risk from parental mosaicism; prenatal diagnosis / preimplantation genetic testing are options when a familial (mosaic) variant is known. MAXO:0000079 genetic counseling.
• Public health / behavioral / immunization: Not applicable.

Sources: FamilieSCN2A clinical info.

14. Other Species / Natural Disease

• Taxonomy / orthologs: SCN2A is conserved across mammals. Mouse ortholog Scn2a (NCBI Gene 110876; MGI); rat Scn2a; conserved across vertebrates. NCBITaxon:10090 (Mus musculus), NCBITaxon:10116 (Rattus norvegicus).
• Natural disease in other species: No well-characterized naturally-occurring SCN2A channelopathy is established in companion animals or wildlife analogous to the human disorder — the animal knowledge base here is dominated by engineered models, not natural disease (check OMIA for any spontaneous variants). This section is largely not applicable beyond experimental models.
• Comparative biology: The developmental expression switch (Na_V1.2 dominant in immature excitatory neurons, partly ceded to Na_V1.6/SCN8A with maturation) is conserved rodent↔human, which is why mouse models are informative. Evolutionary conservation of the four-domain sodium-channel architecture is deep (across the SCN gene family).
• Zoonosis / transmission: Not applicable — genetic disorder, not transmissible.

Sources: Scn2a rodent model review, PMC11601800.

15. Model Organisms

Mouse is the workhorse and the models split neatly along the human GoF/LoF axis:

• LoF / haploinsufficiency model — Scn2a⁺/⁻ (heterozygous knockout): Viable and fertile. Recapitulates the autism/ID + late-seizure end: reduced excitability of immature neurons but hyperexcitable mature neurons; impaired hippocampal excitability, excitatory synaptic drive, LTP, and spatial learning/memory (PMC6582764); anxiety, sociability, memory-flexibility, and hyperactivity phenotypes, with ampakine CX516 rescuing hyperactivity (PMC6437867). Spratt et al. (Neuron 2019) established the dendritic-excitability mechanism. Applications: modeling the ASD/ID arm and testing expression-restoring therapies (CRISPRa, cis-regulation, AAV-Scn2a gene therapy — SFARI 2025).
• GoF models: knock-in of specific human GoF variants recapitulate early-onset seizures/hyperexcitability and are the substrate for testing expression-lowering ASOs (gapmer ASOs reduce seizures in GoF-modeling mice — the preclinical basis for elsunersen; bioRxiv 2020.09.09.289900).
• Conditional / cell-type-specific models: Cre-based conditional knockouts dissect excitatory-neuron-specific contributions and developmental timing.
• In vitro / cellular: Patient iPSC-derived neurons distinguish GoF vs LoF functionally in a human background (J Neurosci 2024); heterologous expression (HEK/Xenopus) for patch-clamp biophysics; dynamic action-potential clamp for functional prediction.

Phenotype recapitulation & limitations: Mouse models reproduce the core electrophysiology and many behaviors, and their GoF/LoF dichotomy mirrors humans well — a genuine strength. Limitations: rodents don't capture human-specific cortical development, the full cognitive/language phenotype, or the precise developmental timing of the Na_V1.2→Na_V1.6 handoff; strain background modifies severity; and behavioral autism analogs are imperfect proxies. For dismech curation, tag mouse/iPSC evidence as MODEL_ORGANISM / IN_VITRO respectively — keep it distinct from human-clinical support for human phenotypes.

Resources: MGI (mouse Scn2a), IMPC/KOMP (knockout alleles), Cellosaurus (iPSC lines), and the FamilieSCN2A-supported model repositories.

Sources: Scn2a rodent model review PMC11601800, Scn2a+/− behavior/CX516, PMC6437867, Hippocampal Scn2a haploinsufficiency, PMC6582764, gene-therapy review.

Curation-ready summary (dismech hooks)

• Module conformance: Primary → epilepsy_excitation_inhibition_imbalance (GoF arm; #Excitation-Inhibition Imbalance). Treatment → antisense_oligonucleotide_therapy (#Pathogenic mRNA Accumulation, RNase-H knockdown, elsunersen). Consider a cardiac_ion_channel_repolarization-style channelopathy framing conceptually, but epilepsy module is the correct fit.
• Key genes/terms: SCN2A (hgnc:10588), Na_V1.2 (UniProt Q99250); GO:0005248, GO:0043194, GO:0019228; CL:0000598 pyramidal neuron; UBERON:0000956 cerebral cortex.
• Anchor PMIDs (verify snippets before YAML): 28379373 (Wolff 2017 Brain — genotype/phenotype + therapeutic implications); 30301539 (Sanders 2018 Trends Neurosci — GoF/LoF framework); 27876397 (Wong 2016 — SCB efficacy in early-onset); Spratt 2019 Neuron (haploinsufficiency mechanism — confirm PMID); iPSC J Neurosci 2024 (44(8):e0692232023).
• Genotype-directed therapy is the headline — curate the GoF→SCB-responsive vs LoF→SCB-resistant split explicitly, with separate evidence for each direction, and the ASO (GoF-lowering) vs upregulation (LoF-raising) therapeutic mirror-image.

The one-line mental model to carry into curation: same gene, two opposite failures of one sodium channel — jammed-open (GoF) burns early with seizures and answers to sodium-channel blockers; jammed-shut (LoF) starves developing circuits into autism/ID and shrugs those same drugs off — and the whole treatment strategy, down to whether you add or subtract the gene's own message, hinges on which way it broke.

One caveat worth repeating for the record: several 2026-dated regulatory items (elsunersen Breakthrough designation, EMBRAVE topline) come straight from company press releases and trial registries — solid for the treatment-pipeline narrative, but they're not peer-reviewed literature, so cite them as evidence_source: OTHER (or the trial's clinicaltrials: reference) rather than dressing them up as clinical-trial primary evidence.